Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 9/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6936409 | 0.86 | OPRD1 (0.52) | OPRD1HPGDOPRM1OPRK1ALDH1A1 | |
| SCHEMBL4576604 | 0.85 | ALDH1A1 (0.65) | OPRD1HPGDOPRM1OPRK1ALDH1A1 | |
| SCHEMBL8527824 | 0.85 | HPGD (0.58) | OPRD1HPGDOPRM1OPRK1ALDH1A1 | |
| SCHEMBL13620473 | 0.85 | OPRD1 (0.48) | OPRD1HPGDOPRM1OPRK1ALDH1A1 | |
| SCHEMBL4830938 | 0.85 | HPGD (0.54) | OPRD1HPGDOPRM1OPRK1ALDH1A1 | |
| SCHEMBL1989199 | 0.83 | OPRD1 (0.63) | OPRD1OPRM1CYP1A2CYP3A4 | |
| SCHEMBL10313331 | 0.83 | OPRD1 (0.46) | OPRD1HPGDOPRM1OPRK1ALDH1A1 | |
| SCHEMBL14108185 | 0.82 | OPRD1 (0.48) | OPRD1HPGDOPRM1OPRK1CYP1A2 | |
| SCHEMBL6780785 | 0.81 | OPRD1 (0.49) | OPRD1HPGDOPRM1OPRK1CYP1A2 | |
| SCHEMBL71266 | 0.81 | OPRD1 (0.54) | OPRD1HPGDOPRM1OPRK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004242-A1 | Oligomer-Diarylpiperazine Conjugates | NEKTAR THERAPEUTICS (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004242-A1 | Oligomer-Diarylpiperazine Conjugates | BIRC5, MTX2, IAPP | OPRD1 2294/4885HPGD 2167/4885OPRM1 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.